MUCAR BT200 Max, Revolutionizing Car Maintenance with a Powerful New Diagnostic Solution
MUCAR continues to push the boundaries of automotive technology. MUCAR, a pioneering name in automotive innovation, has unveiled its latest breakthrough: the MUCAR BT200 Max.
Built for both professional mechanics and carlover owners, this next-generation bluetooth diagnostic tool delivers powerful features at a competitive price—redefining the repair experience for users worldwide, standing out distinctly from existing solutions.
Since its launch in 2021, the MUCAR BT200 Series OBD2 Auto Diagnostics (BT200 Standard & Pro) has earned widespread acclaim for accessing all available system modules and reading ECU information to facilitate vehicle diagnosis. From MUCAR BT200 to MUCAR BT200 Pro, this series was the FIRST Bluetooth car scanner with FULL SYSTEM DIAGNOSIS and LIFE-TIME FREE update and Multi Resets (1 year free) according to individual needs for less than 50 dollars !
Now let's come to 2025, MUCAR BT200 Series makes a strong comeback with the launch of the MUCAR BT200 Max. Crafted by MUCAR for car enthusiasts everywhere, this product delivers extreme value without compromising performance. It elevates every aspect of the automotive journey.
Here is a brief overview of the features of MUCAR BT200 Max: Lifetime free full-system diagnostics
Lifetime free updates in 15 Maintenance Resets
Full OBDII data Access
Bi-Directional control/active test
Covering 98% of cars in the US, Europe and Asia
In addition to the above basic functions, MUCAR BT200 Max also has some highlights:
1.AI fault code analysis: It can easily perform diagnostic scans through the Dollarfix APP. After diagnosis, DF GPT provides error code analysis and answers to car maintenance questions.
2.Compatible with third-party APPs: Works with any app that supports the ELM327 protocol, connecting and performing OBD related functions.
3.Smart sleep: No need to unplug the connector after each use. Even if the connector is plugged in the car for a long time, it will not consume the battery power, which is convenient for next use and don't have to worry about losing it.(Currently only MUCAR supports this feature)
4.Manage overspeed and coolant high-temperature alerts: When the Dollarfix App is open, the App will obtain the vehicle speed and coolant temperature. If they exceed the limit, the App will alarm to protect the safety.
5.Custom Dashboard: Choose preferred OBD data streams and view them with dynamic, real-time visuals.
6.Overvoltage Protection: Safeguards hardware from damage by preventing motherboard burnout during voltage spikes.
Not just smarter on the inside — it's totally upgraded on the outside too! MUCAR BT200 Max features a refined design with a premium gray finish and sleek, clean lines. It's built to look great while delivering top performance. Every detail has been carefully crafted to deliver both functionality and visual appeal, making it not only a reliable tool but also a stylish accessory for any tech-savvy user.
DF AI is a standout feature that makes the MUCAR BT200 Max special. MUCAR is committed to making diagnostic tools smarter with ever-evolving AI technology. Refined through three significant iterations and trained on over ten million diagnostic data points, MUCAR's custom-optimized AI model rivals the decision-making capability of seasoned diagnostic experts. And by the way — the newly launched premium model in H1 2025, the MUCAR 892BT, has received a powerful AI and new feature upgrade, including mileage verification (RESETMULODO), which detects odometer tampering through multi-system data comparison — ensuring accurate, reliable, and trustworthy mileage readings. Wi-Fi connectivity is recommended to ensure timely updates, delivering continuous improvements in performance, stability, and feature capabilities.
Want to learn more about MUCAR's AI? Check out the official AI introduction Blog for a deeper dive.
In addition to MUCAR 892BT, MUCAR has recently launched sibling series — the MUCAR 682 and MUCAR 632 — expanding its portfolio to offer a comprehensive range of diagnostic solutions tailored to diverse user needs.
The following comparison highlights the key features and positioning of each tool:
MUCAR continues to deliver high-value products, time and time again.
With the launch of the MUCAR BT200 Max, MUCAR is not only ushering in a new chapter of car care technology, but also setting a bold new standard for the industry. Whether for DIY enthusiast or professional mechanic, this diagnostic tool combines powerful performance with a smooth, premium design — built to impress and perform.
Just as embodied by the brand color #365ABD, MUCAR is committed to delivering reliable diagnostic services 365 days a year. With relentless innovation and a constant drive to reach new heights
One question remains: Will the efforts earn the trust and recognition of drivers worldwide? The journey continues — stay tuned and time will decide it.
Learn more about MUCAR:
https://linktr.ee/MUCARdiagnostictools
Brand Official website:
https://www.mucarco.com/product/BT200Max
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a minute ago
- Associated Press
Gabelli Global Small and Mid Cap Value Trust Declares Third Quarter Distribution of $0.16 Per Share
RYE, N.Y., Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of The Gabelli Global Small and Mid Cap Value Trust (NYSE:GGZ) (the 'Fund') declared a $0.16 per share cash distribution payable on September 23, 2025 to common shareholders of record on September 16, 2025. The Fund intends to pay a quarterly distribution of an amount determined each quarter by the Board of Trustees. In addition to the quarterly distributions, and in accordance with the minimum distribution requirements of the Internal Revenue Code for regulated investment companies, the Fund may pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the quarterly distributions for that year. Each quarter, the Board of Directors reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Directors will continue to monitor the Fund's distribution level, taking into consideration the Fund's net asset value and the current financial market environment. The Fund's distribution policy is subject to modification by the Board of Directors at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund. All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual's tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their 'net investment income', which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund. If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund's earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder's original investment, it is generally not taxable and would be treated as a reduction in the shareholder's cost basis. Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2025 would include approximately 10% from net investment income, 23% from net capital gains and 67% would be deemed a return of capital on a book basis. This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website ( The final determination of the sources of all distributions in 2025 will be made after year end and can vary from the quarterly estimates. Shareholders should not draw any conclusions about the Fund's investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2025 distributions in early 2026 via Form 1099-DIV. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the Fund's distribution policy and other information about the Fund, call: Bethany Uhlein (914) 921-5546 About The Gabelli Global Small and Mid Cap Value Trust The Gabelli Global Small and Mid Cap Value Trust is a diversified, closed-end management investment company with $144 million in total net assets whose primary investment objective is to achieve long-term capital growth of capital. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities (such as common stock and preferred stock) of companies with small or medium sized market capitalizations. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (OTCQX: GAMI). NYSE – GGZ CUSIP – 36249W104 THE GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST Investor Relations Contact: Bethany Uhlein (914) 921-5546 [email protected]
Yahoo
2 hours ago
- Yahoo
Medical Device Testing Market Size Attains USD 24.32 Bn by 2034
The global medical device testing market is valued at USD 10.77 billion in 2025 and is projected to grow to approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% during the forecast period. Ottawa, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The global medical device testing market size was valued at USD 9.84 billion in 2024 and is projected to reach approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% over the forecast period, according to a study published by Towards Healthcare, a sister firm of Precedence Research. A rise in the need for trustworthy and high-quality medical devices is propelling the expansion of the global market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways Asia-Pacific led the global medical device testing market in 2024. North America is expected to witness rapid expansion during 2025-2034. By service, the biocompatibility tests segment was dominant in the market in 2024. By service, the chemistry tests segment is expected to register significant growth in the coming years. By phase, the clinical segment held the dominating share of the global medical device testing market in 2024. By phase, the preclinical segment is expected to grow at a notable CAGR during 2025-2034. Market Overview & Potential A process in which the evaluation of the safety, efficiency, and performance of medical devices is conducted, termed medical device testing. Across the globe, the global medical device testing market is experiencing growing regulatory strictness, technological breakthroughs, and a rising healthcare sector. In 2025, it comprises major developments in in-vitro diagnostics (IVD), and the execution of the EU's Medical Device Regulation (MDR) around the market. Usually, it encompasses the evaluation, functionality, durability, sterility, biocompatibility, electrical safety, and usability of the medical device. What are the Key Growth Drivers Involved in The Expansion of The Market? In 2025, several growth factors are impacting the overall development of the global medical device testing market. The growing geriatric population associated with chronic concerns is driving demand for diverse medical devices involved in diabetes management, mobility assistance, and remote patient monitoring. Along with this, an emerging strict regulatory landscape, such as the FDA and the EU's MDR, is offering strong testing guidelines for safety and efficacy. Majorly, different developing medical device producers, particularly startups, are highly outsourcing testing to specialized firms, resulting in market growth. Become a valued research partner with us - What are the Key Drifts Involved in the Market? In August 2025, BDC Laboratories, a leading player in cardiovascular device testing solutions, entered into a strategic partnership with the newly established Dilawri Cardiovascular Institute (DCI) to enhance focus on the development and clinical validation of cardiovascular medical devices. In October 2024, NAMSA, a leader in MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global player in medical technology, partnered to expand the regulatory approval and commercialization of Terumo's product portfolio. What is the Emerging Challenge in the Market? The need for significant investment in specialized equipment, skilled personnel, and ongoing compliance efforts is creating a major hindrance in the global medical device testing market. Alongside, the widespread requirement for specialized knowledge and skills in areas like biocompatibility, sterilization, and electrical safety is evolving into a barrier to the development of the market. Regional Analysis Why Did Asia Pacific Dominate the Market in 2024? Across the global medical device testing market, the Asia Pacific was dominant in 2024. China, India, and Japan are experiencing a vital expansion due to increasing economies and growing disposable incomes. This ultimately results in a rise in investment in the healthcare system and medical devices, propelling the adoption of various testing services. Additionally, faster advances in different technologies, such as miniaturization, digitalization, and the development of new materials, are enhancing the need for specialized testing March 2025, UL Solutions Inc., a major player in applied safety science, announced its expansion of Songshan Lake IoT Laboratory in Dongguan, China, to support manufacturers in navigating the complexities of connected product and wireless device testing and market access. What Made North America Significantly Grow in the Market in 2024? During 2025-2034, North America is predicted to expand at a rapid CAGR in the global medical device testing market. Merging high R&D investment by many medical device companies, like the adoption of technologies like AI and automation, in this region, is fueling overall market development. Also, North America is focusing on patient safety and regulatory compliance, especially in the US, which requires rigorous testing throughout the product January 2025, Argon Medical Devices enrolled the first patient in a US-based study exploring a newer catheter-based device for managing blood clots in the lungs. In June 2025, Ash, a leading at-home health testing platform, and Impilo, a leader in offering at-home healthcare, partnered to deliver feasible at-home health monitoring and testing nationwide. You can place an order or ask any questions, please feel free to contact us at sales@ Segmental Insights By service analysis Which Service Led the Medical Device Testing Market in 2024? The biocompatibility tests segment held the largest revenue share of the market in 2024. Around the globe, numerous medical device manufacturers are preferring biocompatibility testing to achieve market acceptance and develop a robust reputation for quality and safety. Along with this, these tests are important for reducing the risk of adverse reactions, infections, and other difficulties linked with medical devices. This leads to ensuring patient safety and improving device efficacy. Whereas the chemistry tests segment is predicted to grow rapidly during 2025-2034. Several advantages of this segment are the assessment of the possible toxicity of medical devices and confirming that they will not react negatively with the body. Additionally, the chemistry tests are widely employed in broader devices, from simple disposables to complex implants, to ensure their safety and regulatory compliance. Primarily, they comprise the identification of chemical compounds of a medical device and examination of probable risks linked with their presence, which further assist in biocompatibility assessment. By phase analysis How did the Clinical Segment Hold a Major Share of the Market in 2024? The clinical segment dominated the global medical device testing market in 2024. Usually, different phases of clinical trials offer significant real-world evidence that assists healthcare professionals in making informed decisions about device usage and expands the continuous optimization of medical devices. A surge in 3D printing and AI in medical device manufacturing is boosting the need for clinical trials to study the performance and safety of these new technologies. Also, the segment is driven by the accelerating need for advanced medical devices, a focus on patient safety and efficacy, and a rise in regulatory scrutiny. The preclinical segment is predicted to witness significant expansion in the studied years. Ongoing developments in biocompatibility testing, microbiology testing, and package validation are widely impacting the development of the preclinical phase of the market. Furthermore, various medical device industries, especially small-scale ones, have a shortage of resources or well-trained personnel to execute complete preclinical testing in-house. This further propels the demand for specialized preclinical testing service providers. Whereas, currently growing diverse chronic diseases are fueling demand for enhanced patient safety, which ultimately relies on the development of the preclinical phase. Get the latest insights on healthcare industry segmentation with our Annual Membership: Recent Developments In July 2025, Siemens Healthineers launched the CN-3000 and CN-6000 Hemostasis Systems for coagulation testing in Canada. In May 2025, Roche unveiled the Elecsys PRO-C3 test for the evaluation of the liver fibrosis severity in individuals with signs of metabolic dysfunction–associated steatotic liver disease (MASLD). In March 2025, Nelson Labs launched a groundbreaking rapid sterility testing to notably expedite product sterility results. In October 2024, UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications, introduced FibGel, a natural injectable hydrogel for permanent implantable medical devices. Medical Device Testing Market Key Players SGS SA Laboratory Corporation of America Holdings Nelson Laboratories, LLC TÜV SÜD Charles River Laboratories Element Minnetonka North America Science Associates Inc. (NAMSA) Eurofins Scientific Pace Analytical Services LLC Intertek Group Plc WuXi AppTec Browse More Insights of Towards Healthcare: The global medical device contract manufacturing market is valued at USD 78.61 billion in 2024, expected to grow to USD 87.14 billion in 2025, and projected to reach approximately USD 220.57 billion by 2034, expanding at a CAGR of 10.86% between 2025 and 2034. The global medical device outsourcing market is estimated at USD 160.3 billion in 2024, rising to USD 180.59 billion in 2025, and forecasted to hit nearly USD 507.89 billion by 2034, advancing at a CAGR of 12.65% during 2025–2034. The global pain management devices market stands at USD 7.68 billion in 2024, increasing to USD 8.41 billion in 2025, and is anticipated to reach around USD 19.1 billion by 2034, growing at a CAGR of 9.54% over the forecast period. The global medical device CRO market is valued at USD 8.49 billion in 2024, set to rise to USD 9.25 billion in 2025, and projected to surpass USD 19.9 billion by 2034, at a CAGR of 8.98% between 2025 and 2034. The global wearable medical devices market is calculated at USD 42.78 billion in 2024, climbing to USD 53.68 billion in 2025, and expected to surge to nearly USD 408.61 billion by 2034, registering a strong CAGR of 25.57% from 2025 to 2034. The global implantable medical devices market is estimated at USD 97.17 billion in 2024, growing to USD 103.14 billion in 2025, and forecasted to reach around USD 176.33 billion by 2034, advancing at a CAGR of 6.14% during 2025–2034. The medical device gaskets & seals market was valued at USD 0.92 billion in 2023 and is projected to expand to USD 1.57 billion by 2034, progressing at a CAGR of 5% from 2024 to 2034. The 3D-printed medical devices market is expected to grow from USD 5.59 billion in 2025 to approximately USD 24.69 billion by 2034, witnessing a robust CAGR of 17.94% over the forecast period. The global endoscopy devices market size is valued at USD 61.1 billion in 2024, projected to increase to USD 63.44 billion in 2025, and estimated to reach USD 88.55 billion by 2034, registering a CAGR of 3.82% between 2025 and 2034. The global rehabilitation equipment market is valued at USD 17 billion in 2024, expected to rise to USD 18.42 billion in 2025, and projected to hit USD 37.34 billion by 2034, expanding at a CAGR of 8.34% from 2025 to 2034. Segments Covered in The Report By Service Biocompatibility Tests Cardiovascular Device's Biocompatibility Tests Orthopedic Device's Biocompatibility Tests Dental Implant Devices' Biocompatibility Tests Dermal Filler's Biocompatibility Tests General Surgery Implantation Devices Biocompatibility Tests Neurosurgical Implantation Devices Biocompatibility Tests Ophthalmic Implantation Device's Biocompatibility Tests Others Chemistry Test Chemical characterization (E&L) Analytical method development and validation Toxicological Risk Assessment and consulting Microbiology & Sterility Test Bioburden Determination Pyrogen & Endotoxin Testing Sterility Test & Validation Antimicrobial Testing Others Package Validation By Phase Preclinical Large animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Small animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Clinical By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 APAC Region: +91 9356 9282 04 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Twin Disc Announces Full Year and Fourth Quarter Results
MILWAUKEE, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Twin Disc, Inc. (NASDAQ: TWIN) today reported results for the fourth quarter and full fiscal year 2025 ended June 30, 2025. Fiscal Full Year 2025 Highlights Sales increased 15.5% year-over-year to $340.7 million Net loss attributable to Twin Disc was ($1.9) million EBITDA* of $19.0 million, including the impact from currency translation loss, stock based compensation, and other items Operating cash flow of $24.0 million and Free cash flow* of $8.8 million Healthy six-month backlog of $150.5 million supported by strong ongoing order activity Fiscal Fourth Quarter 2025 Highlights Sales increased 14.5% year-over-year to $96.7 million Net income attributable to Twin Disc was $1.4 million EBITDA* of $7.0 million, including the impact from currency translation loss, stock based compensation, and other items Operating cash flow of $16.4 million and Free cash flow* of $8.7 million CEO Perspective 'We closed out the fiscal year with our strongest quarter, a reflection of the team's consistent execution and resilience in dynamic markets. Marine and Propulsion led the way with robust defense-driven demand, while Industrial saw steady recovery and increased shipments late in the year. Although oil and gas remained challenged, we continued to advance our electrification strategy with new e-frac activity. Throughout the year, we maintained pricing discipline and protected margins, even as we managed through tariff noise and ongoing cost pressures. Our recent acquisitions expanded our global footprint and diversified our end markets, reinforcing the strength of our platform,' commented John H. Batten, President and Chief Executive Officer of Twin Disc. 'As we enter the new fiscal year, we are in a stronger position both operationally and strategically, supported by a healthy backlog, greater organizational agility, and our integration efforts that are creating new commercial opportunities across regions and segments. Our established presence in the defense market, reinforced by a steady flow of strong customer inquiries, positions us to capture additional growth. Looking ahead, we are committed to driving growth, maintaining disciplined operations, and executing on our long-term value creation strategy,' concluded Mr. Batten. Fourth Quarter and Full-Year ResultsSales for the fiscal fourth quarter 2025 increased 14.5% year-over-year to $96.7 million and fiscal full year 2025 sales increased 15.5% to $340.7 million when compared to the prior fiscal year. Fiscal 2025 fourth quarter and full year sales growth were both driven by demand for the Company's Land-Based Transmissions markets, with strength in Marine and Propulsion Systems, and a stabilization in the Industrial segment. On an organic basis*, which excludes the impacts of acquisitions and foreign currency exchange, fiscal fourth quarter 2025 revenue decreased 8.4% year-over-year, due primarily to reduced shipments of oil and gas transmissions into China. For the fiscal full year 2025, revenue increased 1.0% on an organic basis when compared to the prior fiscal year. Sales by product group (certain amounts have been reclassified from Marine and Propulsion to Other): Product Group Q4 FY25 Sales Q4 FY24 Sales Change (%) (Thousands of $): Marine and Propulsion Systems $53,011 $47,228 12.2% Land-Based Transmissions 26,122 24,989 4.5% Industrial 13,141 7,219 82.0% Other 4,404 4,982 -11.6% Total $96,678 $84,418 14.5% Product Group FY25 Sales FY24 Sales Change (%) (Thousands of $): Marine and Propulsion Systems $201,101 $171,765 17.1% Land-Based Transmissions 80,192 78,519 2.1% Industrial 41,502 25,669 61.7% Other 17,943 19,174 (6.4%) Total $340,738 $295,127 15.5% For the fiscal full year 2025, Twin Disc delivered double-digit growth year-over-year in the European and Asia-Pacific regions including the impact of acquisitions. The distribution of sales across geographical regions shifted, with a greater proportion of sales coming from Europe, and a lower proportion coming from the Asia-Pacific region. Gross profit increased 19.7% to $30.0 million in fiscal fourth quarter 2025 compared to $25.1 million in the prior fiscal year period. Fiscal fourth quarter 2025 gross margin improved approximately 130 basis points to 31.0% from the prior fiscal year period, supported by a favorable product mix and one-time cost capitalization adjustments in Katsa inventory. For the fiscal full year 2025, gross profit increased 11.3% year-over-year to $92.7 million, and gross margin decreased approximately 100 basis points to 27.2% from the prior fiscal year. Marketing, engineering and administrative (ME&A) expenses increased by $4.3 million, or 20.9%, to $24.6 million in the fiscal fourth quarter 2025, compared to $20.4 million in the prior fiscal year period. The increased ME&A expense was primarily driven by the addition of Katsa and Kobelt, in addition to an increase in professional fees and an inflationary impact on wages and benefits. For the fiscal full year 2025, ME&A expense increased 15.1% to $82.4 million, primarily driven by the same factors driving the fourth quarter increase, noted above. Net income attributable to Twin Disc for the fourth quarter of fiscal 2025 was $1.4 million, or $0.10 per diluted share, compared to net income attributable to Twin Disc of $7.4 million, or $0.53 per diluted share, for the fourth quarter of fiscal 2024. For the fiscal full year 2025, the Company generated a net loss attributable to Twin Disc of ($1.9 million), or ($0.14) per diluted share, a decrease of 116.8% and 116.5%, respectively, from fiscal full year 2024. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were $7.0 million in the fiscal fourth quarter 2025, down 40.4% compared to the fourth quarter of fiscal 2024. The year-over-year change was primarily driven by increased currency translation losses, higher operating expenses, and stock based compensation. Fiscal full year 2025 EBITDA decreased 28.3% to $19.0 million from $26.5 million in fiscal full year 2024. This change was largely driven by increased currency translation losses, stock based compensation, and inventory adjustments. Certain items impacting EBITDA for the fourth quarter and full year of fiscal 2025 and 2024 include: (Thousands of $): Q4 FY25 Q4 FY24 FY25 FY24 Restructuring $52 $11 $408 $218 Non-cash stock based compensation 1,389 1,373 4,068 3,383 Non-cash strategic inventory write-down - - 1,579 3,099 Acquisition costs 40 488 839 856 Non-cash bargain purchase gain - (3,724) - (3,724) Currency translation (gain)/loss 2,935 (703) 4,825 (377) Non-cash defined benefit pension amortization 191 (258) 885 (1,076) On a consolidated basis, the backlog of orders to be shipped over the next six months is approximately $150.5 million at the end of the fourth quarter, compared to $133.7 million at the end of the third quarter. As a percentage of six-month backlog, inventory decreased from 103.2% at the end of the third quarter, to 101.0% at the end of the fourth quarter. Compared to the end of fiscal 2024, cash decreased 19.7% to $16.1 million, total debt increased 21.8% to $31.4 million, and net debt* increased $9.6 million to $15.3 million. The increase was primarily attributable to higher long-term debt related to the Katsa and Kobelt acquisitions. CFO PerspectiveJeffrey S. Knutson, Vice President of Finance, Chief Financial Officer, Treasurer and Secretary, stated, 'We're pleased with our financial performance this year, marked by disciplined execution and strong integration progress. Our inventory is well positioned to support demand heading into the new year, and our cash position remains healthy, giving us flexibility to invest in growth while maintaining a strong balance sheet. With continued progress on global manufacturing optimization, we're well equipped to scale efficiently and support sustainable profitability.' Discussion of Results Twin Disc will host a conference call to discuss these results and to answer questions at 9:00 a.m. Eastern time on August 21, 2025. The live audio webcast will be available on Twin Disc's website at To participate in the conference call, please dial (646) 307-1963 approximately ten minutes before the call is scheduled to begin. A replay of the webcast will be available at shortly after the call until August 21, 2026. About Twin Disc Twin Disc, Inc. designs, manufactures, and sells marine and heavy-duty off-highway power transmission equipment. Products offered include marine transmissions, azimuth drives, surface drives, propellers, and boat management systems, as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems. The Company sells its products to customers primarily in the pleasure craft, commercial and military marine markets, as well as in the energy and natural resources, government, and industrial markets. The Company's worldwide sales to both domestic and foreign customers are transacted through a direct sales force and a distributor network. For more information, please visit Forward-Looking StatementsThis press release may contain statements that are forward looking as defined by the Securities and Exchange Commission in its rules, regulations, and releases. The words 'anticipates,' 'believes,' 'intends,' 'estimates,' and 'expects,' or similar anticipatory expressions, usually identify forward-looking statements. The Company intends that such forward-looking statements qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on current expectations and are subject to certain risks and uncertainties that could cause actual results or outcomes to differ materially from current expectations. Such risks and uncertainties include the impact of general economic conditions and the cyclical nature of many of the Company's product markets; foreign currency risks and other risks associated with the Company's international sales and operations; the ability of the Company to successfully implement price increases to offset increasing commodity costs; the ability of the Company to generate sufficient cash to pay its indebtedness as it becomes due; and the possibility of unforeseen tax consequences and the impact of tax reform in the U.S. or other jurisdictions. These and other risks are described under the caption 'Risk Factors' in Item 1A of the Company's most recent Form 10-K filed with the Securities and Exchange Commission, as supplemented in subsequent periodic reports filed with the Securities and Exchange Commission. Accordingly, the making of such statements should not be regarded as a representation by the Company or any other person that the results expressed therein will be achieved. The Company assumes no obligation, and disclaims any obligation, to publicly update or revise any forward-looking statements to reflect subsequent events, new information, or otherwise. *Non-GAAP Financial Information Financial information excluding the impact of asset impairments, restructuring charges, foreign currency exchange rate changes and the impact of acquisitions, if any, in this press release are not measures that are defined in U.S. Generally Accepted Accounting Principles ('GAAP'). These items are measures that management believes are important to adjust for in order to have a meaningful comparison to prior and future periods and to provide a basis for future projections and for estimating our earnings growth prospects. Non-GAAP measures are used by management as a performance measure to judge profitability of our business absent the impact of foreign currency exchange rate changes and acquisitions. Management analyzes the company's business performance and trends excluding these amounts. These measures, as well as EBITDA, provide a more consistent view of performance than the closest GAAP equivalent for management and investors. Management compensates for this by using these measures in combination with the GAAP measures. The presentation of the non-GAAP measures in this press release are made alongside the most directly comparable GAAP measures. Definitions Organic net sales is defined respectively as net sales excluding the recent acquisitions of Katsa and Kobelt while adjusting for the effects of foreign currency exchange. Earnings before interest, taxes, depreciation, and amortization (EBITDA) is calculated as net earnings or loss excluding interest expense, the provision or benefit for income taxes, depreciation, and amortization expenses. Net debt is calculated as total debt less cash. Free cash flow is calculated as net cash provided (used) by operating activities less acquisition of fixed assets. Investors: RiveronTwinDiscIR@ Source: Twin Disc, Incorporated CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except per-share data; unaudited) For the Quarter Ended For the Year Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Net sales $ 96,678 $ 84,418 $ 340,738 $ 295,127 Cost of goods sold 66,660 59,332 246,433 208,709 Cost of goods sold - Other - - 1,579 3,099 Gross profit 30,018 25,086 92,726 83,319 Marketing, engineering, and administrative expenses 24,620 20,356 82,431 71,622 Restructuring expenses 53 11 408 218 Income from operations 5,345 4,719 9,887 11,479 Other (expense) income: Interest expense (855 ) (394 ) (2,646 ) (1,443 ) Bargain purchase gain 3,724 3,724 Other (expense) income, net (2,947 ) 961 (5,472 ) 1,607 (3,802 ) 4,291 (8,118 ) 3,888 Income before income taxes and noncontrolling interest 1,543 9,010 1,769 15,367 Income tax expense 47 1,515 3,368 4,121 Net income (loss) 1,496 7,495 (1,599 ) 11,246 Less: Net earnings attributable to noncontrolling interest, net of tax (72 ) (85 ) (295 ) (258 ) Net income (loss) attributable to Twin Disc, Incorporated $ 1,424 $ 7,410 $ (1,894 ) $ 10,988 Dividends per share $ 0.04 $ 0.04 $ 0.16 $ 0.12 Income (loss) per share data: Basic income (loss) per share attributable to Twin Disc, Incorporated common shareholders $ 0.10 $ 0.54 $ (0.14 ) $ 0.80 Diluted income (loss) per share attributable to Twin Disc, Incorporated common shareholders $ 0.10 $ 0.53 $ (0.14 ) $ 0.79 Weighted average shares outstanding data: Basic shares outstanding 13,897 13,748 13,856 13,683 Diluted shares outstanding 13,971 13,911 13,856 13,877 Comprehensive income Net income (loss) $ 1,496 $ 7,495 $ (1,599 ) $ 11,246 Benefit plan adjustments, net of income taxes (2,153 ) (191 ) (3,399 ) (2,114 ) Foreign currency translation adjustment 16,120 1,587 15,924 657 Unrealized (loss) gain on hedges, net of income taxes (1,491 ) 120 (1,851 ) 46 Comprehensive income 13,972 9,011 9,075 9,835 Less: Comprehensive (loss) income attributable to noncontrolling interest 158 (42 ) 334 182 Comprehensive income attributable to Twin Disc, Incorporated $ 13,814 $ 9,053 $ 8,741 $ 9,653 RECONCILIATION OF CONSOLIDATED NET INCOME (LOSS) TO EBITDA (In thousands; unaudited) For the Quarter Ended For the Year Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Net income (loss) attributable to Twin Disc, Incorporated $ 1,424 $ 7,410 $ (1,894 ) $ 10,988 Interest expense 855 394 2,646 1,443 Income tax expense 47 1,515 3,368 4,121 Depreciation and amortization 4,705 2,484 14,899 9,981 Earnings before interest, taxes, depreciation and amortization (EBITDA) $ 7,031 $ 11,803 $ 19,019 $ 26,533 RECONCILIATION OF TOTAL DEBT TO NET DEBT (In thousands; unaudited) June 30, 2025 June 30, 2024 Current maturities of long-term debt $ 3,000 $ 2,000 Long-term debt 28,446 23,811 Total debt 31,446 25,811 Less cash 16,109 20,070 Net debt $ 15,337 $ 5,741 RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW (In thousands; unaudited) For the Quarter Ended For the Year Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Net cash provided by operating activities $ 16,448 $ 11,499 $ 23,979 $ 33,716 Acquisition of property, plant, and equipment (7,705 ) (1,109 ) (15,157 ) (8,707 ) Free cash flow $ 8,743 $ 10,390 $ 8,822 $ 25,009 RECONCILIATION OF REPORTED NET SALES TO ORGANIC NET SALES (In thousands; unaudited) For the Quarter Ended For the Year Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Net Sales $ 96,678 $ 84,418 $ 340,738 $ 295,127 Less: Acquisitions/Divestitures (16,457 ) - (43,973 ) (2,556 ) Less: Foreign Currency Impact (2,915 ) - (1,423 ) - Organic Net Sales $ 77,306 $ 84,418 $ 295,342 $ 292,571 CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands; except share amounts, unaudited) June 30, 2025 June 30, 2024 ASSETS Current assets: Cash $ 16,109 $ 20,070 Trade accounts receivable, net 58,941 52,207 Inventories, net 151,951 130,484 Other current assets 19,914 16,870 Total current assets 246,915 219,631 Property, plant and equipment, net 69,576 58,074 Right-of-use assets operating lease assets 17,250 16,622 Goodwill 2,892 - Intangible assets, net 13,361 12,686 Deferred income taxes 2,812 2,339 Other noncurrent assets 2,756 2,706 Total assets $ 355,562 $ 312,058 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ 3,000 $ 2,000 Current maturities of right-of use operating lease obligations 3,393 2,521 Accounts payable 38,745 32,586 Accrued liabilities 80,655 62,409 Total current liabilities 125,793 99,516 Long-term debt 28,446 23,811 Right-of-use lease obligations 14,357 14,376 Accrued retirement benefits 11,832 7,854 Deferred income taxes 4,320 5,340 Other long-term liabilities 6,423 6,107 Total liabilities 191,171 157,004 Twin Disc, Incorporated shareholders' equity: Preferred shares authorized: 200,000; issued: none; no par value - - Common shares authorized: 30,000,000; issued: 14,632,802; no par value 42,269 41,798 Retained earnings 125,414 129,592 Accumulated other comprehensive loss 3,730 (6,905 ) 171,413 164,485 Less treasury stock, at cost (482,181 and 637,778 shares, respectively) 7,402 9,783 Total Twin Disc, Incorporated shareholders' equity 164,011 154,702 Noncontrolling interest 380 352 Total equity 164,391 155,054 Total liabilities and equity $ 355,562 $ 312,058 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands; unaudited) June 30, 2025 June 30, 2024 CASH FLOWS FROM OPERATING ACTIVITIES: Net (loss) income $ (1,599 ) $ 11,246 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 14,899 9,981 Gain on sale of assets (98 ) (91 ) Loss on write-down of industrial product inventory 1,579 - Loss on sale of boat management product line and related inventory - 3,099 Gain on Katsa acquisition (3,724 ) Restructuring charges 39 (82 ) Benefit for deferred income taxes (1,581 ) (560 ) Stock compensation expense and other non-cash changes, net 4,107 3,836 Net change in operating assets and liabilities 6,633 10,011 Net cash provided by operating activities 23,979 33,716 CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of property, plant, and equipment (15,157 ) (8,707 ) Acquisition of Katsa, less cash acquired (17,236 ) - Acquisition of Kobelt, less cash acquired - (23,178 ) Proceeds from sale of property, plant, and equipment 147 - Other, net (653 ) (184 ) Net cash used by investing activities (32,899 ) (32,069 ) CASH FLOWS FROM FINANCING ACTIVITIES: Borrowings under long-term debt agreement 6,500 - Borrowings under revolving loan arrangements 122,264 90,534 Repayments of revolving loan arrangements (122,264 ) (81,109 ) Repayments of other long-term debt (2,500 ) (2,010 ) Dividends paid to shareholders (2,284 ) (1,695 ) Dividends paid to noncontrolling interest (306 ) (254 ) Payments of right-of-use finance lease obligations (1,119 ) (921 ) Payments of withholding taxes on stock compensation (1,256 ) (1,791 ) Net cash (used) provided by financing activities (965 ) 2,754 Effect of exchange rate changes on cash 5,924 2,406 Net change in cash (3,961 ) 6,807 Cash: Beginning of period 20,070 13,263 End of period $ 16,109 $ 20,070 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
